title: Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.
abstract: Candida parapsilosis is an increasing cause of bloodstream infections (BSIs) in neonatal intensive care units (NICUs). It has been a persistent problem in the NICU of Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland, since 1987. Fluconazole prophylaxis has been used to control the problem. The number of new infections has, however, increased markedly since September 2000. We assessed fluconazole consumption and occurrence of all Candida species in the NICU from 1991 to 2002. C. parapsilosis bloodstream isolates obtained in the NICU from 1990 to 2002 (n = 26) were genotyped and their fluconazole susceptibility was defined. A low rate of C. parapsilosis BSIs was correlated with high rates of consumption of fluconazole. No emergence of Candida species with primary resistance to fluconazole was detected. However, genotyping with a complex DNA fingerprinting probe revealed that a single strain of C. parapsilosis with decreasing susceptibility to fluconazole was responsible for cross-infections that caused BSIs in the NICU over a 12-year period. The emergence of fluconazole resistance in that strain was observed after more than 10 years of fluconazole prophylaxis.
authors.affiliation: Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland. emmi.sarvikivi@fimnet.fi
authors.forename: Emmi
authors.initials: E
authors.lastname: Sarvikivi
authors.forename: Outi
authors.initials: O
authors.lastname: Lyytikäinen
authors.forename: David R
authors.initials: DR
authors.lastname: Soll
authors.forename: Claude
authors.initials: C
authors.lastname: Pujol
authors.forename: Michael A
authors.initials: MA
authors.lastname: Pfaller
authors.forename: Malcolm
authors.initials: M
authors.lastname: Richardson
authors.forename: Pirkko
authors.initials: P
authors.lastname: Koukila-Kähkölä
authors.forename: Päivi
authors.initials: P
authors.lastname: Luukkainen
authors.forename: Harri
authors.initials: H
authors.lastname: Saxén
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology / Q000517:prevention & control; D018890:Chemoprevention; D025141:Drug Resistance, Fungal; D005260:Female; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D016469:Fungemia / Q000382:microbiology / Q000517:prevention & control; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000382:microbiology* / Q000517:prevention & control; D007363:Intensive Care Units, Neonatal; D008297:Male; D008826:Microbial Sensitivity Tests
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole